Skip to content

Universe Pharmaceuticals INC: 20-F filed 2022-01-31

What Universe Pharmaceuticals INC reported in its annual report (foreign private issuer) filed 2022-01-31 (fiscal FY 2021): 41 published measures, 109 facts as tagged in accession 0001213900-22-004359.

This filing

Form
20-F (annual report (foreign private issuer))
Filed
2022-01-31
Fiscal period
fiscal FY 2021
Accession
0001213900-22-004359 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Universe Pharmaceuticals INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-09-3070,144,781USD
At 2020-09-3028,804,298USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-09-3058,934,353USD
At 2020-09-3020,802,904USD
At 2019-09-3012,384,059USD
At 2018-09-309,681,572USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-09-308,077,908USD
At 2020-09-3010,058,202USD
At 2019-09-303,177,321USD
At 2018-09-306,190,176USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-10-01 to 2021-09-30-2,055,847USD365
2019-10-01 to 2020-09-306,115,157USD366
2018-10-01 to 2019-09-3013,203,755USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-10-01 to 2021-09-30444,505USD365
2019-10-01 to 2020-09-3051,798USD366
2018-10-01 to 2019-09-3086,324USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-10-01 to 2021-09-3047,982,031USD365
2019-10-01 to 2020-09-3030,703,960USD366
2018-10-01 to 2019-09-3033,229,316USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-10-01 to 2021-09-3026,581,809USD365
2019-10-01 to 2020-09-30470,136USD366
2018-10-01 to 2019-09-30-16,003,857USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-10-01 to 2021-09-30-27,059,958USD365
2019-10-01 to 2020-09-30-51,798USD366
2018-10-01 to 2019-09-30-86,033USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-09-3025,058,931USD
At 2020-09-3013,738,979USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-10-01 to 2021-09-302,358,526USD365
2019-10-01 to 2020-09-302,542,211USD366
2018-10-01 to 2019-09-302,101,597USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-09-304,681,353USD
At 2020-09-304,428,064USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-10-01 to 2021-09-3013,590,140USD365
2019-10-01 to 2020-09-3010,251,725USD366
2018-10-01 to 2019-09-309,752,829USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-09-3050,481,064USD
At 2020-09-3023,279,921USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-10-01 to 2021-09-30101,604USD365
2019-10-01 to 2020-09-30123,760USD366
2018-10-01 to 2019-09-30129,268USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-09-3011,210,428USD
At 2020-09-308,001,394USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-09-305,310,526USD
At 2020-09-302,691,193USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2021-09-30178,483USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2021-09-3015,573,742USD
At 2020-09-3010,871,778USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-10-01 to 2021-09-3011,736,037USD365
2019-10-01 to 2020-09-303,842,095USD366
2018-10-01 to 2019-09-303,654,656USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2021-09-302,462,542USD
At 2020-09-301,906,232USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-10-01 to 2021-09-3025,326,177USD365
2019-10-01 to 2020-09-3014,093,820USD366
2018-10-01 to 2019-09-3013,407,485USD365

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-10-01 to 2021-09-3022,655,854USD365
2019-10-01 to 2020-09-3016,610,140USD366
2018-10-01 to 2019-09-3019,821,831USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-10-01 to 2021-09-305,465,662USD365
2019-10-01 to 2020-09-30583,125USD366
2018-10-01 to 2019-09-30618,437USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-09-3021,750,000shares
At 2020-09-3016,000,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-09-3029,279,159USD
At 2020-09-303,679,000USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2021-09-302,088,759USD
At 2020-09-30895,390USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2021-09-3010,461,600USD
At 2020-09-309,523,016USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-09-305,780,247USD
At 2020-09-305,094,952USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2021-09-30178,483USD
At 2020-09-30174,776USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-10-01 to 2021-09-3013,678,478USD365
2019-10-01 to 2020-09-3010,100,433USD366
2018-10-01 to 2019-09-309,653,062USD365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-10-01 to 2021-09-3011,319,952USD365
2019-10-01 to 2020-09-307,558,222USD366
2018-10-01 to 2019-09-307,551,465USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-10-01 to 2021-09-303,296,844USD365
2019-10-01 to 2020-09-301,703,424USD366
2018-10-01 to 2019-09-301,457,393USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-10-01 to 2021-09-30441,355USD365
2019-10-01 to 2020-09-30404,948USD366
2018-10-01 to 2019-09-30413,199USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2020-10-01 to 2021-09-305,523USD365
2019-10-01 to 2020-09-305,131USD366
2018-10-01 to 2019-09-305,232USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2020-10-01 to 2021-09-3088,338USD365
2019-10-01 to 2020-09-30-151,292USD366
2018-10-01 to 2019-09-30-99,767USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2020-10-01 to 2021-09-303,026,867USD365
2019-10-01 to 2020-09-302,552,097USD366
2018-10-01 to 2019-09-302,141,222USD365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2020-10-01 to 2021-09-30-668,341USD365
2019-10-01 to 2020-09-30-9,886USD366
2018-10-01 to 2019-09-30-39,625USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-10-01 to 2021-09-30149,303USD365
2019-10-01 to 2020-09-30157,528USD366
2018-10-01 to 2019-09-30135,717USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-10-01 to 2021-09-303,867,457USD365
2019-10-01 to 2020-09-304,107,520USD366
2018-10-01 to 2019-09-30-665,485USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-10-01 to 2021-09-30451,634USD365
2019-10-01 to 2020-09-30-888,607USD366
2018-10-01 to 2019-09-30-5,586,177USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-10-01 to 2021-09-302,457,337USD365
2019-10-01 to 2020-09-30639,427USD366
2018-10-01 to 2019-09-30-924,444USD365

Inspect the source

Entity
Universe Pharmaceuticals INC / CIK 0001809616
Captured
2026-09-21T17:28:24.267Z
SEC response SHA-256
97e9e5f7aa9211a23b29663f0a1c64c35854b6ad847c07fae0970a291b42ffb4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001809616.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))